TG Therapeutics (TGTX) Cantor Global Healthcare Conference 2025 summary

Key business updates and strategic priorities

• Announced a new $100 million share buyback authorization, with $70 million executed in August following a previous $100 million program.

• BRIUMVI launch has exceeded internal and Wall Street expectations every quarter since its February 2023 debut.

• Initial focus was on healthcare provider education; now shifting to direct-to-patient marketing, including TV and connected TV ads.

• Direct-to-consumer investments are increasing, with patient awareness surveys showing positive trends.

• No significant impact observed from competing products, including subcutaneous Ocrevus.

Market performance and financial guidance

• CD20 dynamic share is over 50% and trending upward, with total share expected to lag by about five years.

• BRIUMVI captures about one in three new IV CD20 patients; steady market share growth continues.

• Guidance philosophy remains conservative, aiming for high confidence in targets; current year guidance is $570–$575 million.

• Gross-to-net expected to remain stable for long-term modeling; current net price likely to persist.

• Over 95% national coverage for BRIUMVI, with no anticipated changes in access.

Product differentiation and competitive landscape

• BRIUMVI’s efficacy, tolerability, and convenience (one-hour infusion) are key differentiators; also priced at a 25% discount to competitors.

• Subcutaneous BRIUMVI pivotal trials will test both every-other-month and quarterly dosing, aiming for a rapid autoinjector format with low injection volume.

• SubQ formulation could nearly double the market opportunity, as subQ currently represents 40% of the CD20 market.

• Biosimilar Ocrevus is viewed as an opportunity, not a threat, due to BRIUMVI’s differentiation and existing discount.